Pulmonary Function in Patients Recovering From COVID19 Infection : a Pilot Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05074927

Acronym

EFRUPIC

Enrollment

Registered

2021-10-12

Start date

2022-01-31

Completion date

2026-07-13

Last updated

2026-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

Lung function, Diaphragm ultrasonography, Chronic Inflammatory Rheumatism

Brief summary

The current state of knowledge shows the presence of respiratory sequelae after acute infection with COVID-19 and the importance of these long-term respiratory dysfunctions have to be determined. Aim of our study is describe diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from SARS-CoV-2 pneumonia at 3 and 6 months after the acute episode.

Detailed description

patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) will be included to follow the impact of severe acute respiratory syndrom coronavirus 2 on pulmonary function, diaphragm function and exercice capacity. Surviving patients will be evaluated at 3 and 6 months after hospital discharge. The assesment will include diaphragm ultrasonography, spirometry (FEV1,FVC), carbon monoxide transfert (TLCO adjusted for haemoglobin), inspiratory an expiratory respiratory muscle strength (Pimax and Pemax) and 6 minutes walk distance (6MWD).The main outcome will be diaphragm excursion assessed by ultrasound.

Interventions

DIAGNOSTIC_TESTdiaphragm ultrasonography

For all patients with confirmed COVID-19 who had been discharged from CHRU Hospital in Limoges (France) : diaphragm ultrasonography at 3 (M0) and 6 months (M3) after the end of his hospitalisation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* SARS-CoV-2 infection proven by RT-PCR. * Patient hospitalised for the management of SARS-CoV-2 infection and included 3 months after the end of his hospitalisation at the CHU of Limoges. * Patient of legal age. * Patient affiliated to a social security regime. * Patient having given informed consent

Exclusion criteria

* Known pregnancy. * Patients who are contraindicated to perform the 6-minute walk test. * Patients unable to understand or adhere to the protocol. * Patients deprived of liberty. * Patients under court order, tutorship or curatorship. * Minor patients

Design outcomes

Primary

Measure	Time frame	Description
The change diaphragmatic amplitude using diaphragm ultrasonography in patients recovering from SARS-CoV-2 pneumonia.	at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges	Diaphragmatic amplitude assessed by ultrasound at M0 and M3.

Secondary

Measure	Time frame	Description
the correlation between the values of diaphragmatic travel and Pi max and Pe max at M0 and M3.	at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges	Diaphragmatic amplitude, PI max and PE max
the difference in diaphragmatic amplitude between M0 and M3.	at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges	Diaphragmatic amplitude at M0 and M3
the difference in FEV1 between M0 and M3.	at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges	FEV1 at M0 and M3.
the difference in FVC between M0 and M3.	at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges	FVC at M0 and M3.
the difference in DLCO between M0 and M3.	at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges	DLCO at M0 and M3.
the difference in Pi max and Pe max between M0 and M3.	at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges	PI max and PE max at M0 and M3
dyspnoea between M0 and M3.	at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges	mMRC dyspnoea scale at M0 and M3.
the functional capacity between M0 and M3.	at 3 (M0) and 6 months (M3) after the end of his hospitalisation at the CHU of Limoges	6-minutes walk test distance at M0 and M3.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORVINCENT François, Pr

CHU Limoges

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 27, 2026